Nexalin Technology shares are trading higher after being awarded a patent by the USPTO related to its deep intracranial frequency stimulation device for the treatment of Alzheimer's and dementia.
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology shares are trading higher after being awarded a patent by the USPTO for its deep intracranial frequency stimulation device aimed at treating Alzheimer's and dementia.
June 20, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology has been awarded a patent by the USPTO for its deep intracranial frequency stimulation device, which is designed to treat Alzheimer's and dementia. This news has led to a rise in the company's share price.
The award of a patent is a significant milestone for Nexalin Technology, as it provides intellectual property protection and validates the potential of their device. This positive development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100